At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Véronique Diéras (Institut Curie, Paris, France) discusses the phase 2 PALOMA-1 study of the cyclin-dependent kinase 4/6 inhibitor, palbociclib, in combination with letrozole versus letrozole alone as first-line treatment for women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. The addition of palbociclib to letrozole significantly improved progression-free survival in this patient population. A phase 3 trial has begun.
Allergy & Immunology
